Keros Therapeutics Files 8-K on Operations and Financials
Ticker: KROS · Form: 8-K · Filed: May 6, 2025 · CIK: 1664710
| Field | Detail |
|---|---|
| Company | Keros Therapeutics, Inc. (KROS) |
| Form Type | 8-K |
| Filed Date | May 6, 2025 |
| Risk Level | low |
| Sentiment | neutral |
Sentiment: neutral
Topics: 8-K, financials, operations
TL;DR
Keros Therapeutics dropped an 8-K on May 6th covering financials and operations. Check it for the latest.
AI Summary
Keros Therapeutics, Inc. filed an 8-K on May 6, 2025, reporting on its results of operations and financial condition, as well as financial statements and exhibits. The filing details the company's corporate structure, including its state of incorporation (Delaware) and fiscal year end (December 31).
Why It Matters
This filing provides an update on Keros Therapeutics' financial health and operational status, which is crucial for investors to assess the company's performance and future prospects.
Risk Assessment
Risk Level: low — This is a routine 8-K filing providing standard corporate and financial information, not indicating any immediate material events or risks.
Key Players & Entities
- Keros Therapeutics, Inc. (company) — Registrant
- May 6, 2025 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of incorporation
- 001-39264 (identifier) — Commission File Number
- 81-1173868 (identifier) — I.R.S. Employer Identification No.
- 1050 Waltham Street, Suite 302 (address) — Principal executive offices
- Lexington, Massachusetts (location) — Principal executive offices city and state
- 02421 (zip_code) — Principal executive offices zip code
- 617-314-6297 (phone_number) — Registrant's telephone number
FAQ
What is the primary purpose of this 8-K filing by Keros Therapeutics?
The primary purpose of this 8-K filing is to report on Keros Therapeutics' results of operations and financial condition, as well as to provide financial statements and exhibits.
When was the earliest event reported in this filing?
The earliest event reported in this filing was on May 6, 2025.
In which state is Keros Therapeutics incorporated?
Keros Therapeutics, Inc. is incorporated in Delaware.
What is the principal executive office address for Keros Therapeutics?
The principal executive office address for Keros Therapeutics is 1050 Waltham Street, Suite 302, Lexington, Massachusetts 02421.
What is the Commission File Number for Keros Therapeutics?
The Commission File Number for Keros Therapeutics is 001-39264.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on May 6, 2025 regarding Keros Therapeutics, Inc. (KROS).